Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29]
Corresponding Author of This Article
Sung-Hsin Kuo, MD, PhD, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. shkuo101@ntu.edu.tw
Research Domain of This Article
Hematology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hematol. May 6, 2014; 3(2): 29-43 Published online May 6, 2014. doi: 10.5315/wjh.v3.i2.29
Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases
Shih-Hung Yang, Chiun Hsu, Ann-Lii Cheng, Sung-Hsin Kuo
Shih-Hung Yang, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
Shih-Hung Yang, Chiun Hsu, Ann-Lii Cheng, Sung-Hsin Kuo, Department of Oncology, National Taiwan University Hospital, Taipei 100, Taiwan
Shih-Hung Yang, Chiun Hsu, Ann-Lii Cheng, Sung-Hsin Kuo, Cancer Research Center, National Taiwan University College of Medicine, Taipei 100, Taiwan
Chiun Hsu, Ann-Lii Cheng, Sung-Hsin Kuo, Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 100, Taiwan
Ann-Lii Cheng, Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
Author contributions: All authors contributed equally to the work.
Author contributions: Yang SH conducted the literature review and drafted the article; Hsu C and Cheng AL wrote the manuscript; Kuo SH revised the content and approved the final version for publication.
Supported by Research grants NSC 101-2321-B-002-032 and NSC 101-2314-B-002-157-MY3 from the National Science Council, Taiwan; NHRI-EX102-10239BI, and NHRI-EX102-10239BI from the National Health Research Institutes, Taiwan; and DOH100-TD-B-111-001 from the Department of Health, Taiwan
Correspondence to: Sung-Hsin Kuo, MD, PhD, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan. shkuo101@ntu.edu.tw
Telephone: +886-2-23123456 Fax: +886-2-23123456
Received: November 13, 2013 Revised: January 27, 2014 Accepted: March 17, 2014 Published online: May 6, 2014 Processing time: 188 Days and 15.7 Hours
Core Tip
Core tip: Anti-CD20 monoclonal antibodies are widely used for the treatment of hematological malignancies and autoimmune disorders. These agents produce prolonged B-cell depletion and significant immune suppression. In this review, we summarized the clinical use of anti-CD20 monoclonal antibodies and the reports of acute or chronic hepatitis associated with the use of these agents. Most of these hepatitis cases had viral etiologies. We discuss the mechanisms of the hepatitis caused by these drugs. These infections not only interrupted the immunotherapy but are also associated with high mortality and morbidity. This review may prompt physicians to monitor patients’ liver function more closely and to provide adequate prophylaxis while using these agents.
